Skip to main content

Table 4 Results of this analysis

From: One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis

Outcomes which were assessed

RR with 95% CI

P value

I2 value (%)

Major adverse cardiac events

0.69 [0.54–0.88]

0.002

0

Target lesion failure

0.66 [0.48–0.91]

0.01

0

All-cause mortality

0.79 [0.51–1.22]

0.28

32

Cardiac death

0.75 [0.42–1.33]

0.32

3

Myocardial infarction

0.80 [0.53–1.20]

0.28

15

Any revascularization

0.80 [0.59–1.10]

0.18

0

Target lesion revascularization

0.67 [0.39–1.14]

0.14

0

Target vessel revascularization

0.74 [0.48–1.13]

0.16

0

Total stent thrombosis

1.13 [0.60–2.13]

0.70

0

Definite stent thrombosis

1.12 [0.38–3.31]

0.84

0

Probable stent thrombosis

0.87 [0.37–2.09]

0.76

0

Possible stent thrombosis

1.19 [0.50–2.87]

0.69

0

Late stent thrombosis

1.00 [0.17–5.72]

1.00

0

  1. RR Risk ratio, CI confidence intervals